intensity therapeutics is a connecticut based biopharmaceutical company whose mission is to create safer and more efficacious chemotherapy treatments. intensity therapeutics is a preclinical, in vivo stage company seeking investors interested in helping to advance the company’s technology and products.
Company profile
Ticker
INTS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
461488089
INTS stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
8-K
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
12 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
13 Nov 23
8-K
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
5 Sep 23
S-8
Registration of securities for employees
22 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.69 mm | 6.69 mm | 6.69 mm | |||
Cash burn (monthly) | (no burn) | 830.17 k | (no burn) | |||
Cash used (since last report) | n/a | 5.65 mm | n/a | |||
Cash remaining | n/a | 1.04 mm | n/a | |||
Runway (months of cash) | n/a | 1.3 | n/a |
Institutional ownership, Q2 2023
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 170.24 mm |
Total shares | 28.56 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Walleye Capital | 28.36 k | $169.04 mm |
Glassman Wealth Services | 200.00 | $1.19 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Daniel Donovan | Stock Option (right to buy Common Stock) Common Stock | Grant | Acquire A | No | No | 5.19 | 50,000 | 259.50 k | 50,000 |
6 Mar 24 | John M Wesolowski | Stock Option (right to buy Common Stock) Common Stock | Grant | Acquire A | No | No | 5.19 | 25,000 | 129.75 k | 25,000 |
6 Mar 24 | Emer Leahy | Stock Option (right to buy Common Stock) Common Stock | Grant | Acquire A | No | No | 5.19 | 50,000 | 259.50 k | 50,000 |
6 Mar 24 | Mark A Goldberg | Stock Option (right to buy Common Stock) Common Stock | Grant | Acquire A | No | No | 5.19 | 50,000 | 259.50 k | 50,000 |
6 Mar 24 | Lewis H Bender | Stock Option (right to buy Common Stock) Common Stock | Grant | Acquire A | No | No | 5.19 | 33,574 | 174.25 k | 33,574 |
6 Mar 24 | Lewis H Bender | Stock Option (right to buy Common Stock) Common Stock | Grant | Acquire A | No | No | 5.19 | 464,805 | 2.41 mm | 464,805 |
Press releases
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
2 Apr 24
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
26 Mar 24
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
14 Mar 24
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
14 Mar 24
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
21 Feb 24